-
Mashup Score: 6
AbstractPurpose:. We present the results of a post hoc tumor tissue analysis from the phase 3 MILO/ENGOT-ov11 study (NCT01849874).Patients and Methods:. Mutation/copy-number analysis was performed on tissue obtained pre-randomization. The Kaplan–Meier method was used to estimate progression-free survival (PFS). Unbiased univariate analysis, Cox regression, and binary logistic regression were used to test associations between mutation status and outcomes, including PFS and binary response by local RECIST 1.1.Results:. MILO/ENGOT-ov11 enrolled 341 patients, ranging in age from 22 to 79, from June, 2013 to April, 2016. Patients were randomized 2:1 to binimetinib or physician’s choice of chemotherapy (PCC). The most commonly altered gene was KRAS (33%). In 135 patients treated with binimetinib with response rate (RR) data, other detected MAPK pathway alterations included: NRAS (n = 11, 8.1%), BRAF V600E (n = 8, 5.9%), RAF1 (n = 2, 1.5%), and NF1 (n = 7, 5.2%). In those with and without MAP
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Publish Faster. Publish Smarter. - Aries Systems Corporation - 7 month(s) ago
Privacy Policy Japanese Version Aries Systems Corporation 50 High Street, Suite 21 North Andover, MA 01845 © 2023 Aries Systems Corporation. its licensors, and contributors. All rights reserved,…
Source: www2.cloud.editorialmanager.comCategories: General Medicine News, Hem/OncsTweet-
RT @ESMO_Open: Where to submit your Phase II study? Consider ESMO Open - IF 7.3 https://t.co/XX5d9ajOuk #ESMO23 #ESMO2023
-
-
Mashup Score: 0In the literature: September 2023 - 7 month(s) ago
Author links open overlay panel A. Lamarca 1 2, V. Moreno 3, V. Gambardella 4 5, A. Cervantes 4
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
In the literature: September 2023 https://t.co/fsHG146q1c
-
-
Mashup Score: 11ESMO Guidance for Reporting Oncology real-World evidence (GROW) - 7 month(s) ago
The use of real-world data (RWD) for generating real-world evidence (RWE) to complement interventional clinical trial-based research is rapidly increasing. This evolving field is particularly prevalent in oncology with a growing number of publications and increased use of RWD in medicine regulation in recent years.1, 2, 3, 4 Improving the quality of RWE is crucial for patients, the scientific community and health care authorities. A comprehensive literature search of the existing guidance for reporting
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @ArndtVogel: 🔥off the press: ESMO Guidance for Reporting Oncology real-World evidence (GROW) @Annals_Oncology https://t.co/f81jxXmRZc 👉…
-
-
Mashup Score: 15Co-op CARs for targeting acute myeloid leukemia - 7 month(s) ago
Chimeric antigen receptor (CAR) T cell therapies are limited by antigen escape and on-target/off-tumor toxicity. In addressing these challenges, Haubner et al. develop an “IF-BETTER” strategy. Their combinatorial chimeric co-stimulatory receptor with an attenuated CAR enhances acute myeloid leukemia (AML) killing while protecting healthy progenitors, highlighting the potential to leverage cooperative CAR designs.
Source: www.cell.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @Cancer_Cell: Online Now: Co-op CARs for targeting acute myeloid leukemia https://t.co/Z1V5Ogm5Yk https://t.co/2PnEmsHNnI
-
-
Mashup Score: 2Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial - 8 month(s) ago
AbstractPurpose:. Despite promising preclinical studies, toxicities have precluded combinations of chemotherapy and DNA damage response (DDR) inhibitors. We hypothesized that tumor-targeted chemotherapy delivery might enable clinical translation of such combinations.Patients and Methods:. In a phase I trial, we combined sacituzumab govitecan, antibody–drug conjugate (ADC) that delivers topoisomerase-1 inhibitor SN-38 to tumors expressing Trop-2, with ataxia telangiectasia and Rad3-related (ATR) inhibitor berzosertib. Twelve patients were enrolled across three dose levels.Results:. Treatment was well tolerated, with improved safety over conventional chemotherapy-based combinations, allowing escalation to the highest dose. No dose-limiting toxicities or clinically relevant ≥grade 4 adverse events occurred. Tumor regressions were observed in 2 patients with neuroendocrine prostate cancer, and a patient with small cell lung cancer transformed from EGFR-mutant non–small cell lung cancer.Con
Source: aacrjournals.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @CCR_AACR: Phase 1 Study: Sacituzumab Govitecan and Berzosertib. https://t.co/GrT4a7JXTo https://t.co/Xokezq8bh0
-
-
Mashup Score: 31
PURPOSE To evaluate the efficacy and safety of tucatinib and trastuzumab in patients with previously treated human epidermal growth factor receptor 2–positive (HER2+) metastatic biliary tract cancer (mBTC). METHODS SGNTUC-019 (ClinicalTrials.gov identifier: NCT04579380) is an open-label phase II basket study evaluating the efficacy and safety of tucatinib and trastuzumab in patients with HER2-altered solid tumors. In the biliary tract cancer cohort, patients had previously treated HER2 overexpressing or amplified (HER2+) tumors (identified with local testing) with no prior HER2-directed therapy. The primary end point was confirmed objective response rate (cORR) per investigator assessment. Patients were treated on a 21-day cycle with tucatinib (300 mg orally twice daily) and trastuzumab (8 mg/kg intravenously followed by 6 mg/kg every 3 weeks). RESULTS Thirty patients were enrolled. As of data cutoff (January 30, 2023), the median duration of follow-up was 10.8 months. The cORR was 46.
Source: ascopubs.orgCategories: Latest Headlines, Oncologists1Tweet-
RT @ArndtVogel: Tucatinib & Trastuzumab for HER2 2+ Metastatic Biliary Tract Cancer @JCO_ASCO https://t.co/IQloT7qeLj 👉ORR 46.7%, mPFS 5.5…
-
-
Mashup Score: 2Will Organoids Fill the Gap towards Functional Precision Medicine? - 8 month(s) ago
Precision medicine approaches for solid tumors are mainly based on genomics. Its employment in clinical trials has led to somewhat underwhelming results, except for single responses. Moreover, several factors can influence the response, such as gene and protein expression, the coexistence of different genomic alterations or post-transcriptional/translational modifications, the impact of tumor microenvironment, etc., therefore making it insufficient to employ a genomics-only approach to predict response. Recently, the implementation of patient-derived organoids has shed light on the possibility to use them to predict patient response to drug treatment. This could offer for the first time the possibility to move precision medicine to a functional environment.
Source: www.mdpi.comCategories: Latest Headlines, Oncologists1Tweet-
Will Organoids Fill the Gap towards Functional Precision Medicine? https://t.co/VTOSGh848o #mdpijpm via @JPM_MDPI
-
-
Mashup Score: 18Keeping It in the Family: HER3 as a Target in Brain Metastases - 9 month(s) ago
Summary. In 180 patients with metastatic breast cancer and non–small cell lung cancer (NSCLC), HER3 expression was found in >70% of brain metastases (BM). HER3-targeting antibody–drug conjugates have demonstrated efficacy in HER3-expressing metastatic breast cancer and NSCLC. Thus, HER3 expression by IHC may be a biomarker for development of HER3-targeting BM-specific therapeutics.See related article by Tomasich et al., p. 3225
Source: aacrjournals.orgCategories: Latest Headlines, Oncologists1Tweet-
RT @CCR_AACR: Keeping it in the family: HER3 as a target in brain metastases. https://t.co/1YWU1paY7V https://t.co/ciIH4tgJEi
-
-
Mashup Score: 23
The exact mechanisms that govern clonal dynamics and selection during early tumorigenesis remain largely elusive. Ceresa et al. provide experimental and mathematical evidence that MYC-dependent competition between individual clones is one driving force of brain tumor evolution, adding a winner/loser aspect to the picture that complements existing concepts.
Source: www.cell.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @Cancer_Cell: The winner takes it all: Competition drives clonal selection in gliomagenesis https://t.co/AGLnpNxWRn
-
RT @CCR_AACR: Phase 3 Study: Low-grade serous ovarian cancer and MAPK pathway alterations (MILO/ENGOT-ov11). https://t.co/Ko64Cf6Pxa https:…